Oryzon Genomics (ORY) KOL Event summary

Introduction and agenda

• Event focused on the development of a novel treatment for agitation and aggression in borderline personality disorder (BPD), with presentations, a fireside chat, and a Q&A session.

• Nearly 80 attendees registered, highlighting strong interest in the topic.

KOL background and credentials

• Panel included leading psychiatrists and researchers with extensive experience in BPD, aggression, and drug development.

• Experts have contributed to the development and validation of key clinical outcome measures used in trials.

Market insights and analysis

• BPD affects 1-2% of the global population, with high rates of suicide and significant societal and economic burden.

• No FDA-approved drugs exist for BPD; current treatments are off-label and lack robust efficacy.

• Agitation and aggression are core symptoms, leading to functional impairment and high healthcare utilization.